Crinetics Pharmaceuticals CRNX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Crinetics Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's EBITDA margin?
- Crinetics Pharmaceuticals (CRNX) reported EBITDA margin of -2,997.5% in Q1 2026.
- How has Crinetics Pharmaceuticals's EBITDA margin changed year-over-year?
- Crinetics Pharmaceuticals's EBITDA margin increased by 93.9% year-over-year, from -49,143.9% to -2,997.5%.
- What is the long-term trend for Crinetics Pharmaceuticals's EBITDA margin?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EBITDA margin has grown at a -9.4% compound annual growth rate (CAGR), from -9,905.4% to -6,664.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.